Menu Back to Real-World-Evidence-Conference

Program Committee

  • Nancy A. Dreyer, PhD, MPH, FISPE
    Nancy A. Dreyer, PhD, MPH, FISPE • Chief Scientific Officer & SVP
    IQVIA, United States
  • Steven A. Anderson, PhD
    Steven A. Anderson, PhD • Director, Office of Biostatistics and Epidemiology, CBER
    FDA, United States
  • Dorothee B Bartels, PhD, MSc
    Dorothee B Bartels, PhD, MSc • Head of Global Real World Evidence and Digital Science
    UCB, Germany
  • Brian Bradbury, PhD, MA
    Brian Bradbury, PhD, MA • Vice President, Center for Observational Research
    Amgen, United States
  • Paul M. Coplan, DrSc, MBA, MSc, FISPE
    Paul M. Coplan, DrSc, MBA, MSc, FISPE • VP, Medical Device Epidemiology & Real-World Data Analytics
    Johnson & Johnson, United States
  • Marni Hall, PhD, MPH
    Marni Hall, PhD, MPH • Vice President, Clinical Evidence
    IQVIA, United States
  • James Harnett, PharmD, MS
    James Harnett, PharmD, MS • Executive Director, Health Economics and Outcomes Research
    Regeneron Pharmaceuticals, Inc. , United States
  • Jingyu (Julia) Luan, PhD
    Jingyu (Julia) Luan, PhD • Senior Director, Global Regulatory Affairs, BioPharmaceuticals R&D
    AstraZeneca, United States
  • David Martin, MD, MPH
    David Martin, MD, MPH • Vice President, Clinical Safety and Risk Management
    Moderna, United States
  • Robert Reynolds, DrSc, FISPE
    Robert Reynolds, DrSc, FISPE • Vice President, Epidemiology & Patient-Centered Outcomes
    GSK, United States
  • Debra Schaumberg, DrSc, MPH
    Debra Schaumberg, DrSc, MPH • Vice President, Epidemiology & Head Strategic and Scientific Affairs
    Evidera | PPD, United States
  • Mark Stewart, PhD
    Mark Stewart, PhD • Vice President, Science Policy
    Friends of Cancer Research, United States
Load More

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download